An evaluation of bleeding risks Among Nonvalvular Atrial Fibrillation (NVAF) Patients Treated With Dabigatran, Rivaroxaban, Apixaban, or Warfarin
Latest Information Update: 24 Nov 2016
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate; Rivaroxaban; Warfarin
- Indications Stroke; Thrombosis
- Focus Therapeutic Use
- 24 Nov 2016 New trial record
- 16 Nov 2016 Results (n=17,127) presented at the 89th Annual Scientific Sessions of the American Heart Association.